These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33316246)

  • 1. Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study.
    Schmedt N; Enders D; Walker J; Garbe E; Douros A
    Am J Med; 2021 May; 134(5):606-613.e6. PubMed ID: 33316246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.
    Wang A; Yang K; Wang T; Zhang N; Tang H; Feng X
    Diabetes Metab Res Rev; 2020 Jan; 36(1):e3174. PubMed ID: 31050384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
    Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
    Filion KB; Lix LM; Yu OH; Dell'Aniello S; Douros A; Shah BR; St-Jean A; Fisher A; Tremblay E; Bugden SC; Alessi-Severini S; Ronksley PE; Hu N; Dormuth CR; Ernst P; Suissa S;
    BMJ; 2020 Sep; 370():m3342. PubMed ID: 32967856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study.
    Schmedt N; Andersohn F; Walker J; Garbe E
    Diabetes Obes Metab; 2019 Jan; 21(1):52-60. PubMed ID: 30047217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
    Dawwas GK; Smith SM; Park H
    Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
    Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
    JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.
    Dave CV; Schneeweiss S; Patorno E
    Diabetes Obes Metab; 2019 Feb; 21(2):434-438. PubMed ID: 30207042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.
    Fadini GP; Bonora BM; Mayur S; Rigato M; Avogaro A
    Diabetes Obes Metab; 2018 Mar; 20(3):740-744. PubMed ID: 29053207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
    Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study.
    Sainsbury C; Wang J; Gokhale K; Acosta-Mena D; Dhalla S; Byne N; Chandan JS; Anand A; Cooper J; Okoth K; Subramanian A; Bangash MN; Taverner T; Hanif W; Ghosh S; Narendran P; Cheng KK; Marshall T; Gkoutos G; Toulis K; Thomas N; Tahrani A; Adderley NJ; Haroon S; Nirantharakumar K
    Diabetes Obes Metab; 2021 Jan; 23(1):263-269. PubMed ID: 32991065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
    Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
    BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
    Chen HY; Huang JY; Siao WZ; Jong GP
    Cardiovasc Diabetol; 2020 Jun; 19(1):73. PubMed ID: 32503541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: A propensity score-matched cohort study.
    Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1629-1639. PubMed ID: 31646732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.